Gyre Therapeutics (GYRE) 10-K2018 FY Annual report

Filed: 8 Mar 19, 6:08am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: AAV, ABR, absence, Academy, Allied, antidrug, Apcintex, Bethesda, binding, Blouse, BU, cessation, chart, condensed, conference, constraint, customary, DalcA, Dalcinonacog, dAMD, defect, distinct, eighteen, elaparvovec, eleven, encoding, ESPP, expedient, Fannie, fatal, fell, fidanacogene, fitusiran, Flexible, fold, forecast, forecasted, Freddie, Freeline, frequency, fulfill, GlobalData, Green, Haemophilia, histocompatibility, HLA, Home, hypertension, immunogenic, immunogenicity, Importantly, indistinguishable, IRA, Israel, kDa, land, Lessor, leukocyte, Mac, Mae, margin, Maryland, MHC, mimicking, Ministry, mutation, nAb, nadir, neuronal, NHP, notably, Onpattro, Padua, paired, pairwise, path, PEG, PK, predecessor, premium, primate, promised, quantification, Rabbit, reaction, Rebinyn, residual, rest, resume, rotated, Ryan, Sanofi, sequelae, serpine, Seventeen, shutdown, silico, swelling, Takeda, TFPI, thrombotic, timeline, toxicology, transgene, Translational, Ukraine, unchanged, uniQure, unmodified, unqualified, version, visit, vol, waned, wildtype

Removed: administering, alternate, anniversary, applied, assay, assured, bifurcate, biotech, Canada, choose, collectability, commensurate, convert, coordinate, correction, divided, effected, efficient, element, enabling, enhancement, entitle, estimable, expressing, extinguishment, fifteen, forfeiture, graph, impairment, instructing, irrevocable, ISTH, lab, leverage, mice, nonlinearity, operated, Overview, planning, poster, prepayment, proportional, redeemed, regularly, reimburse, renamed, renewing, repeat, satisfying, scaffold, select, Selick, session, sharing, Society, steering, sublease, subleased, Toronto, transferring, TRGT, undelivered, whichever, workforce

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

GYRE similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Catalyst Biosciences, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Nassim Usman, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 7, 2019

/s/ Nassim Usman, Ph.D.

Nassim Usman, Ph.D.

President and Chief Executive Officer